News | Atrial Fibrillation | April 12, 2022

Zio by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF

atrial fibrillation

Image credit: Getty Images


April 12, 2022 –  iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement of cardiac care, announces the results of three clinical research studies presented at The American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The new clinical evidence:

  • Further validates the Zio service as a viable solution for the early detection of atrial fibrillation (AF),1 helping undiagnosed populations effectively seek treatment before more serious problems can occur.
  • Shows that the Zio service can positively impact hospital resources2 – a crucial benefit during the continued COVID-19 pandemic.
  • Supports the need for monitoring post-TAVR discharge in high-risk patient populations.3

“As the healthcare system continues to progress towards value-based medicine, we recognize that providers are increasingly challenged to improve clinical outcomes for patients while controlling costs,” said Dietra Jones, Executive Vice President, Clinical Operations at iRhythm. “We are excited that these new data continue to demonstrate that Zio’s clinical accuracy is beneficial in directing patient care across a variety of settings, while improving clinical workflows and hospital capacity. We are also particularly encouraged to see further evidence of Zio’s ability to support early detection and diagnosis of AF in moderate-risk populations.”

The Syncope study, titled “Syncope Pathway Using Live Ambulatory Monitoring Streamlines ER Patient Disposition,” found that Zio AT was able to monitor and aid in diagnosis of qualified syncope patient candidates in an outpatient setting. Implementation of Zio AT allowed health systems to safely monitor patients upon discharge, avoiding a potential 24-48 hour hospital stay. Additionally, 8.2% of patients had an arrhythmia event triggering an MD notification. Nearly half (46%) of these occurred after 48 hours (longer than atypical inpatient stay) – demonstrating the importance of 14-day monitoring with Zio AT. Finally, it was concluded that use of Zio AT saved the healthcare system an estimated 136 inpatient hospitalization days.

The GUARD-AF study, titled “A Randomized Clinical Trial Of Screening For Atrial Fibrillation With A 14-day Patch Monitor: Analysis Of ECG Recordings From The GUARD-AF Study,” reports the initial findings in 5,713 patients who wore the Zio XT monitor. Among the older primary care population in the study, 4.5% had AF detected within two weeks of monitoring: 0.5% of screened participants had persistent AF and 4% had paroxysmal AF detected.   

Lastly, research highlighted in the Rutgers-TAVR study, titled “Ambulatory Electrocardiographic Monitoring Following Transcatheter Aortic Valve Replacement (TAVR) In Different Age Groups,” demonstrates that monitoring with Zio AT post-TAVR discharge can identify AF, high degree atrioventricular block (HAVB), and supraventricular tachycardia (SVT) in patients who are at risk for arrhythmic disorders. During monitoring, in which patients wore the device for up to 14 days, the most common arrhythmias were AF (25%) followed by HAVB (7%) and SVT > 30 secs (6%). The results support the need for monitoring post-TAVR discharge in high-risk patient populations.

Click here to learn more about iRhythm.

Additional coverage from ACC22.

Reference:

1 Daniel E. Singer et al. A Randomized Clinical Trial Of Screening For Atrial Fibrillation With A 14-day Patch Monitor: Analysis Of ECG Recordings From The Guard-AF Study. Presented at: American College of Cardiology’s 71st Annual Scientific Session & Expo; April 2-4, 2022; Washington, DC.
2 Bobbi L. Hoppe et al. Syncope Pathway Using Live Ambulatory Monitoring Streamlines ER Patient Disposition. Presented at: American College of Cardiology’s 71st Annual Scientific Session & Expo; April 2-4, 2022; Washington, DC.
3 Alexis K. Okoh et al. Ambulatory Electrocardiographic Monitoring Following Transcatheter Aortic Valve Replacement (TAVR) In Different Age Groups. Presented at: American College of Cardiology’s 71st Annual Scientific Session & Expo; April 2-4, 2022; Washington, DC.

 

Related Content

News | Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science ...

Home May 02, 2022
Home
News | Atrial Fibrillation

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
News | Atrial Fibrillation

March 9, 2022 – Point-of-care screening for atrial fibrillation (A-fib) using a new generation of handheld ...

Home March 09, 2022
Home
News | Atrial Fibrillation
February 28, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the ...
Home February 28, 2022
Home
News | Atrial Fibrillation
February 16, 2022 – A new way of treating arrhythmias, including atrial fibrillation (AF) — the most common heart ...
Home February 16, 2022
Home
Feature | Atrial Fibrillation

Improved short-term monitoring methods for patients with stroke risk can increase early detection of atrial fibrillation ...

Home December 07, 2021
Home
News | Atrial Fibrillation

November 17, 2021 — People with atrial fibrillation (AFib) who underwent individualized testing to discover triggers for ...

Home November 17, 2021
Home
Subscribe Now